Kartos Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Redwood City CA United States (2017)

Organization Overview

First Clinical Trial
2018
NCT03662126
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kartos Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Myeloproliferative Disorders (Phase 2)

Polycythemia (Phase 2)

Polycythemia Vera (Phase 2)

Primary Myelofibrosis (Phase 2)

Thrombocythemia, Essential (Phase 2)

Thrombocytosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 9